|
|
|
Substance Name: Palbociclib [USAN:INN]
RN: 571190-30-2
UNII: G9ZF61LE7G
InChIKey: AHJRHEGDXFFMBM-UHFFFAOYSA-N
Notes
- Has antineoplastic activity; specific inhibitor of cyclin-dependent kinases 4 & 6.
- Specific inhibitor of cyclin-dependent kinases 4 & 6.
NCI: An orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6), thereby inhibiting retinoblastoma (Rb) protein phosphorylation early in the G1 phase leading to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of cell cycle progression.(NCI Thesaurus)
Molecular Formula
- C24-H29-N7-O2
Molecular Weight
- 447.5401
Classification Codes
- Antineoplastic Agents
- Enzyme Inhibitors
- Protein Kinase Inhibitors
* denotes mobile formatted website
Links to Resources
NLM Resources (File Locators)
Other Resources (Internet Locators)
Search for this InChIKey on the Web
Names and Synonyms
Name of Substance
- Palbociclib [USAN:INN]
Synonyms
- 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one
- Ibrance
- Palbociclib
- PD 0332991
- PD 332991
- PD-0332991
- PD0332991
- UNII-G9ZF61LE7G
Systematic Name
- Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-
Registry Numbers
CAS Registry Number
- 571190-30-2
FDA UNII
- G9ZF61LE7G
System Generated Number
- 0571190302